{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+%28Placebo+Control%29&page=57",
    "query": {
      "intervention": "Saline (Placebo Control)",
      "page": 57
    },
    "page_size": 10
  },
  "pagination": {
    "page": 57,
    "page_size": 10,
    "total_count": 3531,
    "total_pages": 354,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+%28Placebo+Control%29&page=58&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+%28Placebo+Control%29&page=56&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T05:53:12.967Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02509312",
      "title": "Prospective Effect of Intravenous Ketorolac on Opioid Use, EBL and Complications Following Cesarean Delivery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Analgesia, Obstetrical",
        "Postpartum Hemorrhage",
        "Opioid Use",
        "Nonsteroidals (NSAIDs)Toxicity",
        "Coagulation Defect; Postpartum",
        "Postoperative Pain",
        "Ketorolac Adverse Reaction",
        "Blood Loss, Postoperative"
      ],
      "interventions": [
        {
          "name": "Ketorolac",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University Hospitals Cleveland Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 70,
      "start_date": "2016-05",
      "completion_date": "2017-10",
      "has_results": true,
      "last_update_posted_date": "2022-06-07",
      "last_synced_at": "2026-10-28T05:53:12.967Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02509312"
    },
    {
      "nct_id": "NCT01903330",
      "title": "ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "ERC1671",
          "type": "DRUG"
        },
        {
          "name": "GM-CSF",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Oral Control (Sucrose pill)",
          "type": "DRUG"
        },
        {
          "name": "Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%))",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab/Bevacizumab Biosimilar",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Epitopoietic Research Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2014-03",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2025-03-05",
      "last_synced_at": "2026-10-28T05:53:12.967Z",
      "location_count": 3,
      "location_summary": "Orange, California • Boston, Massachusetts",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01903330"
    },
    {
      "nct_id": "NCT01713400",
      "title": "Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft vs. Host Disease"
      ],
      "interventions": [
        {
          "name": "Ustekinumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus (TAC)",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 54,
      "start_date": "2013-02-25",
      "completion_date": "2018-06-14",
      "has_results": true,
      "last_update_posted_date": "2020-03-04",
      "last_synced_at": "2026-10-28T05:53:12.967Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01713400"
    },
    {
      "nct_id": "NCT07214311",
      "title": "Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Prosthetic-joint Infection"
      ],
      "interventions": [
        {
          "name": "PLG0206",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Peptilogics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 240,
      "start_date": "2026-02-03",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-26",
      "last_synced_at": "2026-10-28T05:53:12.967Z",
      "location_count": 16,
      "location_summary": "Sarasota, Florida • Tamarac, Florida • Shreveport, Louisiana + 13 more",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07214311"
    },
    {
      "nct_id": "NCT05099965",
      "title": "Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cytomegalovirus Infections",
        "HIV Infections",
        "Vaccine"
      ],
      "interventions": [
        {
          "name": "CMV-MVA Triplex",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 94,
      "start_date": "2021-11-02",
      "completion_date": "2025-10-08",
      "has_results": true,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-28T05:53:12.967Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05099965"
    },
    {
      "nct_id": "NCT01773707",
      "title": "CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Abnormal Glucose Tolerance",
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "CTLA4-Ig (Abatacept)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "6 Years to 45 Years"
      },
      "enrollment_count": 212,
      "start_date": "2013-03",
      "completion_date": "2022-12-14",
      "has_results": true,
      "last_update_posted_date": "2024-06-06",
      "last_synced_at": "2026-10-28T05:53:12.967Z",
      "location_count": 16,
      "location_summary": "San Francisco, California • Stanford, California • Denver, Colorado + 12 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01773707"
    },
    {
      "nct_id": "NCT00285779",
      "title": "Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lichen Planus"
      ],
      "interventions": [
        {
          "name": "Etanercept",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2006-08",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2018-03-21",
      "last_synced_at": "2026-10-28T05:53:12.967Z",
      "location_count": 12,
      "location_summary": "Stanford, California • Atlanta, Georgia • Louisville, Kentucky + 7 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00285779"
    },
    {
      "nct_id": "NCT06651788",
      "title": "Does Ethyl Chloride Spray Work?",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Injection Fear",
        "Injection Pain Prevention",
        "Injection Complication"
      ],
      "interventions": [
        {
          "name": "Ethyl Chloride",
          "type": "OTHER"
        },
        {
          "name": "Cold Saline Spray",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 246,
      "start_date": "2025-04-01",
      "completion_date": "2028-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-10-28T05:53:12.967Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06651788"
    },
    {
      "nct_id": "NCT02978183",
      "title": "Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "ST266",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline (0.9% NaCl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Noveome Biotherapeutics, formerly Stemnion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2016-12",
      "completion_date": "2017-11",
      "has_results": true,
      "last_update_posted_date": "2023-04-10",
      "last_synced_at": "2026-10-28T05:53:12.967Z",
      "location_count": 2,
      "location_summary": "Andover, Massachusetts • Memphis, Tennessee",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02978183"
    },
    {
      "nct_id": "NCT04232657",
      "title": "Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Spinal Cord Injury (=3 Years)",
        "Sublesional Bone Loss Secondary to SCI"
      ],
      "interventions": [
        {
          "name": "Romosozumab",
          "type": "DRUG"
        },
        {
          "name": "Denosumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 36,
      "start_date": "2021-03-01",
      "completion_date": "2026-08-24",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-10-28T05:53:12.967Z",
      "location_count": 2,
      "location_summary": "West Orange, New Jersey • The Bronx, New York",
      "locations": [
        {
          "city": "West Orange",
          "state": "New Jersey"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04232657"
    }
  ]
}